Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Data ReadoutnafamostatPositive

AI Analysis

Summary

Talphera announced Q2 2026 financial results with NEPHRO CRRT clinical study of nafamostat now 75% enrolled and expected to complete in 2026. Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, representing positive regulatory recognition in an estimated 200,000-patient annual U.S. market.

Clinical Trial Data

Outcome Details

NEPHRO CRRT clinical study 75% enrolled, expected completion in 2026

Importance:6/10

Sentiment:

0.60

clinical trial progressnafamostatCRRT anticoagulationKDIGO guidelinesmarket expansionQ2 2026 results

Related Companies

$TLPH

Read the original article

Published by PR Newswire Clinical Trials on August 12, 2026 8:05 PM

Read Original